Skip to main content


We’d like to understand how you use our websites in order to improve them. Register your interest.

Association Between the Presence of CCR5-specific Antibodies and Long Term Non Progression

Most transmitted HIV-1 strains use CCR5 as coreceptor. Antibodies (Abs) to CCR5 have been detected in highly exposed to HIV-1 but uninfected subjects, thus they could be involved in HIV protection. To assess whether these Abs may also contribute to slow HIV-disease progression, we searched for anti-CCR5 Abs in 499 subjects, including 87 Long Term Non Progressors (LTNP), 70 Progressors, 135 HIV+ HAART treated, and 207 seronegative donors. We found anti-CCR5 Abs in a fraction of LTNP (22.9%), but not in the other populations studied (p < 0.0001). These Abs efficiently prevent infection of HIV-R5 strains representing subtypes B, C and A by inducing a stable and long last down regulation of CCR5 on surface of T lymphocytes. Follow-up studies showed that the loss of anti-CCR5 Abs, occurred in some subjects, was significantly associated with a progression toward disease. Thus, the anti-CCR5 Abs could be relevant to vaccine design and therapeutics.

Author information



Corresponding author

Correspondence to Lucia Lo palco.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lo palco, L., Pastori, C., Uberti-Foppa, C. et al. Association Between the Presence of CCR5-specific Antibodies and Long Term Non Progression. Retrovirology 2, P130 (2005).

Download citation


  • Infectious Disease
  • Cancer Research
  • Vaccine Design
  • Seronegative Donor
  • Uninfected Subject